idorsia Value Stock - Dividend - Research Selection
Market price: 21,38 CHF
Idorsia Ltd Fundamental data and company key figures of the share
|Annual reports in CHF|
|Net operating cash flow||-364.667.000|
|Free cash flow||-373.932.992|
|Liabilities & Shareholders equity||1.435.360.000|
|Diluted shares outstanding||166.447.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||3.645.397.248,00 USD|
|Indices||STOXX EUROPE 600|
|Raw Data Source||IFRS in Millionen CHF|
Description of the company
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.